ISSN 1866-8836
Клеточная терапия и трансплантация

Common variable immunodeficiency in a child. A case report

Andrey V. Kozlov, Tatiana A. Bykova, Anastasia S. Borovkova, Maria Yu. Averjanova, Varvara N. Ovechkina, Elena V. Morozova, Ludmila S. Zubarovskaya, Nikolay N. Mamaev, Boris V. Afanasyev
R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Chair of Hematology, Transfusiology and Transplantation, First St. Petersburg State I. Pavlov Medical University, St. Petersburg, Russia
doi 10.18620/ctt-1866-8836-2017-6-4-60-66


Primary immunodefi ciency syndromes are relatively rare medical conditions that are oft en misdiagnosed because of unspecifi c clinical presentation that mimics other more common diseases. Incidence of combined common variable immunodefi ciency (CVID) is ca. 1 case per 30.000 European population. Usually, a delay of several years is observed between onset and diagnosis. CVID is the most frequent primary immunodefi ciency aft er 4 years of life. The key symptom to establish the disorder is hypogammaglobulinemia.
The aim of this article is to demonstrate current trends in diagnostics of common variable immunodefi ciency (CVID). The present case report describes a 10-year old girl with four major internationally approved criteria of common variable immunodefi ciency (CVID), and specific lung involvement. Malignant conditions were excluded. NGS genetic study did not detect any gene mutation which could be responsible for CVID or related syndromes (ALPS, HLH). Hence, the CVID remains a diagnosis of exclusion. Despite replacement with intravenous immunoglobulins, the lung function in our patient continued to deteriorate that necessitated initiation of immunosuppressive treatment.


Primary immunodefi ciency, common variable immunodeficiency, diagnostic criteria, autoimmune complications.


Primary immunodefi ciency (PID) is a relatively rare medical condition that oft en mimics infectious, autoimmune or malignant diseases. Common variable immunodefi ciency is the most common PID in children aft er 4 years of age and adults. Inherited CVID is revealed in only 20% of patients, showing autosomal recessive or autosomal dominant inheritance, while the rest of cases seem to occur sporadically [1]. In 2014, diagnostic criteria for CVID were revised by European Society of Immune Defi ciencies (ESID), and its major features were established (Table 1). Th ose signs include increased susceptibility to infections, autoimmune manifestations, unexplained polyclonal lymphoproliferation, marked decrease of IgG and IgA with or without low IgM levels, poor antibody response to vaccines (and/or absent isohemagglutinins), low switched memory B cells. Secondary hypogammaglobulinemia should be excluded. Variable manifestations reflect a possibly diff erent genetic background of the disease. At the present time, however, any specifi c mutations can be detected only in 30% of CVID cases, even with such a comprehensive method as whole exome sequencing [2].
Incidence of CVID is ca. 1 case per 30.000 European population. Clinical manifestation of the disease may be at any age, with a fi rst peak at 5 to 10 years and second, between 20 and 30 years. [3]. Common variable immunodefi ciency is oft en diagnosed in children, being associated with high mortality in this group. [4]. Diagnostic criteria have been established, aiming to suspect PID in children including frequent infections of ears, sinuses and lungs, recurrent abscesses, persistent rash aft er fi rst year of age, ineffi ciency of long-lasting treatment with antibiotics, inability to gain weight and growth, as well as family history of PID. Despite awareness of health care providers, a delay of several years is observed between first symptoms and diagnosis of PID [5]. This fact demonstrates that CVID is a diagnostic challenge, since it is often not considered. During diagnostic search, a wide spectrum of disorders may be considered at diff erential diagnosis. Detection of antibody defi ciency is an important clue to suggest a CVID diagnosis. In general, CVID may be regarded as a diagnosis of exclusion. Autoimmune complications are, generally, common in PID and may manifest as initial symptoms in some cases. Only 25% of CVID patients present with common infections as the only symptom. In most cases, the CVID symptoms are associated with immune dysregulation [6]. Benign generalized hypertrophy of lymphoid tissues is more common in CVID than lymphoma [7]. Lungs are aff ected by infections and uncontrollable infl ammation in up to 30%, and early development of bronchiectasis is often a key to CVID diagnosis [8].
The main approaches to CVID management are IVIG replacement therapy, adequate infectious control and, in severe cases, immunosuppressive treatment. Th e only option to cure CVID is allogeneic hematopoietic stem cell transplantation, but its administration is rather limited in this clinical setting due to high toxicity. In case of severe and refractory hemolytic anemia, splenectomy may be a treatment option. Th erefore, existence of life-saving management strategies, together with timely diagnosis increases chances for treatment success and underlines the necessity of awareness among medical staff [9].
In this report, we present a clinical case of a child with CVID which manifested with multiple autoimmune problems and progressive lung disease.

Case description

A 10-year-old female patient (PKD) with severe pancytopenia, giant splenomegaly, generalized lymphadenopathy, multiple lesions in lungs and febrile neutropenia was admitted to clinic R.Gorbacheva Memorial Institute with preliminary diagnosis of unverifi ed hemoblastosis in March 2016. The initial diagnosis was suspected based on above mentioned characteristic clinical symptoms and laboratory data (Table 2-5). Analysis demonstrated moderate anemia, leukopenia and thrombocytopenia, slightly elevated transaminases and triglycerides, decreased fibrinogen and immunoglobulins. At the moment the most probable diagnosis consistent with laboratory fi ndings was hematological disorder. Hypogammaglobulinemia at that time was explained as a consequence of lymphopenia and wasn’t attributed to primary immunodeficiency. No cases of PID were reported in the family history. The child didn’t previously suff er from recurrent or unusual or seasonal infections. At the age of 6 years, the patient had an episode of autoimmune hemolytic anemia which responded to Prednisolone treatment. Severe hemolytic anemia was the only registered autoimmune disorder phenomenon that never relapsed.
Diagnostic workup allowed to exclude bone marrow involvement. Bone marrow aspirate and trephine biopsy showed no signs of clonal proliferation or aplasia. Cytogenetic analysis of bone marrow demonstrated normal karyotype. Molecular-biologic analyses of genes associated with hemoblastosis (t8;21, inv16, t15;17, t9;22, FLT3, NPM1, WT1, EVI-1, MLL, t4;11, del (1) SIL/TAL, t1;19, t9;22, t12;21) were negative. Lymphoproliferative disorder was suspected as a possible primary diagnosis due to generalized lymphadenopathy and splenomegaly.
Giant splenomegaly with hypersplenism that resulted in life-threatening severe pancytopenia were indications for splenectomy with dissection of enlarged regional lymph nodes. It appeared to be a therapeutic and diagnostic option. Splenectomy performed at 5th May 2016 was followed by recovery of peripheral blood counts, but hypogammaglobulinemia still persisted despite normal lymphocyte counts (See Fig. 1 for dynamics of immunoglobulins and lymphocytes). Aft er splenectomy, total number of lymphocytes raised above 1000 cells per mcL, and all major lymphocyte subpopulations raised to normal ranges (number of CD4+ > 300 cells per mcL; number of CD8+ cells > 250 per mcL, number of CD19+ cells > 170 per mcL, and number of CD56+ cells > 70 cells per mcL).
Histological and immunohistochemical analysis of removed spleen and lymph nodes demonstrated non-specifi c reactive changes that were not associated with any malignant disease (revised by 2 independent pathologists: Prof. V. V. Baykov and Prof. U. A. Krivolapov). Presence of enterovirus and Herpes simplex type 1/2 virus was shown in spleen and lymph nodes by PCR assays and confi rmed by immunohistochemistry. Blood samples were negative for viral, bacterial and fungal infections.
CT scanning prior to splenectomy revealed generalized lymphadenopathy of mediastinal and abdominal lymph nodes (Fig. 2A), and multiple lesions in lungs (Fig. 2B). Repeated microbiological cultures of bronchoalveolar lavage still were negative for bacterial, viral and fungal pathogens. Since the patient has recently travelled to Egypt, visceral leishmaniosis was also suspected, due to fever, hepatosplenomegaly and pancytopenia evolving after the trip. However, hypogammaglobulinemia (instead of hypergammaglobulinemia typical to leishmaniosis), negative serological and PCR results, as well as absence of leishmania species in bone marrow aspirate allowed to rule out this diagnosis.
A, mediastinal lymphadenopathy with enlarged lymph nodes marked with black arrows.
B, multiple lesions in lungs in a patient with CVID. Numerous chaotic lesions (maximal size of 12х10 mm) are registered in lungs, with indefi nite margins and peribronchial wall thickening.

The diagnostic search also included Gaucher disease. Analysis of glucocerebrosidase activity in blood was performed at the Research Centre for Medical Genetics (Russian Academy of Sciences, Moscow). The enzyme activity was within reference ranges, without a decrease typical to this genetic disorder.
The patient remained diagnostically unclear. There was no defi nitive evidence of malignancy, thus three non-malignant disorders were considered in differential diagnosis at the moment. They included: hemophagocytic lymphohistiocytosis (HLH), autoimmune lymphoproliferative syndrome (ALPS), and a primary immunodefi ciency (PID). All these diseases share joint clinical signs and pathogenic mechanisms, being attributed to a common class of primary immunodefi ciency syndromes [10].
HLH is a real problem for health care providers, in terms of diagnostic and therapeutic issues. Our patient had four criteria consistent with HLH: fever, splenomegaly, cytopenia and hypertriglyceridemia with hypofi brinogenemia (Tables 2 and 3). Hemophagocytosis in bone marrow or spleen, hyperferritinemia and HLH-specifi c mutations were absent (PRF1, STXBP2, STX1, UNC13D), NK-cell activity in peripheral blood was normal. To establish diagnosis, according to Revised Diagnostic Guidelines for HLH, at least five of diagnostic criteria should be fulfilled, or HLH mutations should be present [11]. Hence, HLH was dismissed because only 4 criteria were present in the patient.
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by malfunction in apoptosis of lymphocytes that leads to excessive lymphoproliferation. Presence of lymphadenopathy and splenomegaly, hemolytic anemia in previous history are characteristic to ALPS, but low level of double-negative CD3+/CD8-/CD4-/TCRαβ+ mature lymphocytes in peripheral blood was not consistent with this diagnosis. Mutations in FAS gene were not found upon whole genome sequencing (University of Dusseldorf, see data in Appendix). Absence of double-negative T lymphocytes and mutations in FAS gene made the diagnosis of ALPS very unlikely.
Due to severe persistent hypogammaglobinemia in the patient, a work-up for CVID was done. Absolute count of switched memory B-cells was checked (0.48%), and it proved to be decreased (reference range 1-40%) that is consistent with diagnosis of CVID (Table 5).
The whole exome sequencing of the patient leukocytes has been performed at University of Dusseldorf using the primary Immunodefi ciency gene panel. The screening did not reveal any candidate genes considered related to primary immunodeficiency, autoimmune lymphoproliferative disorder, HLH or inherited lung disorders (Table 6).


According to the established clinical criteria (Table 1), a CVID diagnosis was confi rmed, based on persisting hypogammaglobulinemia, decreased count of switched memory B-cells (CD27+IgM-IgG-), autoimmune complications (hemolytic anemia) and non-malignant lymphoproliferative syndrome. Lung involvement shown in the child may occur in 30% of patients with CVID, being an unfavorable prognostic sign. Sarcoid-like granuloma, organizing pneumonia, lymphocytic interstitial pneumonitis and nonspecifi c interstitial pneumonia are the most common types of histological fi ndings in aff ected lungs of CVID patients [13]. Hence, the CVID diagnosis is based on constellation of several non-specifi c criteria, while excluding other, less probable, clinical conditions.
The patient is now receiving regular infusions of intravenous immunoglobulins and level of immunoglobulin G is maintained at normal values. However, pulmonary complications of CVID still persist and slowly diminish with time. Lung biopsy has been performed, demonstrating granulomatous pneumonitis without any signs of malignancy. Immunosuppression with Rituximab was initiated due to progressing autoimmune problems and respiratory failure. The granulomatous pneumonitis is currently the only one and leading autoimmune disorder in the patient.
Prognosis for the presented patient is uncertain due to progressive lung involvement. Further treatment options may consist of glucocorticosteroids, cyclosporine A, sirolimus, cyclophosphamide, hydroxychloroquine, azathioprine, methotrexate, etanercept, infl iximab and other immunosuppressive agents. If further respiratory deterioration will occur despite immunosuppressive treatment and IVIG, allogeneic hematopoietic stem cell transplantation and lung transplantation may be considerable options in this patient.


The present case report describes a 10-year old girl with major internationally approved criteria of common variable immunodefi ciency (CVID), and specifi c lung involvement. Malignant conditions were excluded. NGS genetic study did not detect any gene mutation which could be responsible for CVID or related syndromes (ALPS, HLH). Hence, the CVID remains a diagnosis of exclusion, the attending doctor should suspect PID in clinical settings in cases of hypogammaglobulinaemia, non-specified lymphoproliferation, autoimmune features and absence of malignant disorder.


Th e authors are much appreciated to Dr. Ute Fischer from the University of Düsseldorf (Germany) who performed whole exome sequencing in this patient, and to thank Dr. Polina Stepensky from Hadassah Medical Center, Jerusalem (Israel) for valuable advices on this diagnostic procedure for the patient.

Conflicts of interest

No conflict interests are declared.


1. Vořechovský I, Cullen M, Carrington M, Hammarström L, Webster ADB. Fine mapping of IGAD1 in IgA defi ciency and common variable immunodefi ciency: identification and characterization of haplotypes shared by aff ected members of 101 multiple-case families. J Immunology. 2000; 164:4408–4416.
2. Maff ucci P, Filion C A, Boisson B, Itan Y, Shang L, Casanova J L, Cunningham-Rundles C. Front Immunol. 2016; (7):220.
3. Glocher E, Ehl S, Grimbacher B. Common variable immunodeficiency in children. Current opinion in pediatrics. 2007; 19:685-692.
4. Vukic EJ, Cunningham-Rundles C. Common variable immunodefi ciency in children: clinical and immunological features of patients diagnosed before the age of 13. J Allergy Clin Immunol. 2004: 113(2), S39.
5. Salzer U, Warnatz K, Hartmut PH. Common variable immunodeficiency – an update. Arthritis Research & Th erapy.2012:14:223.
6. Aleinikova OV, Fedorova AS, Sharapova SO. Should allogeneic hematopoietic stem cell transplantation be a treatment option for patients with Nijmegen breakage syndrome? Belarusian experience. Cell Th er Transplant. 2015; 4(1-2):31-36.
7. Gompels MM, Hodges E, Lock RJ, Angus B, White H, Larkin A, Chapel HM, Spicett GP, Misbah SA, Smith JL. Lymphoproliferative disease in antibody defi ciency: a multi- centre study, Associated Study Group. Clin Exp Immunol. 2003; 134(2): 314–320.
8. Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodefi ciency. Ann Allergy Asthma Immunol. 2007;98(1):1-8; quiz 8-11, 43.
9. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodefi ciencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164 Suppl 2:2-5.
10. Al-Herz W, Bousfi ha A, Casanova J-L, Chatila T, Conley M E, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM., Sullivan K, Tang MLK. Primary immunodefi ciency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodefi ciency. Front Immunol. 2014; 5:162.
11. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediat Blood Cancer. 2007;48(2):124-131.
12. Ochs D. Hans et al. Primary Immunodefi ciency diseases. A Molecular and Genetic Approach (3rd Edition). 2014. Publisher: Oxford University Press.
13. Prasse A, Kayser G, Warnatz K. Common variable immunodeficiency-associated granulomatous and interstitiallung disease. Curr Opin Pulm Med. 2013;19(5):503-509.

Volume 6, Number 4
12/27/2017 10:03:02 pm

Download PDF version

doi 10.18620/ctt-1866-8836-2017-6-4-60-66

Back to the list